JP2015505299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505299A5 JP2015505299A5 JP2014540570A JP2014540570A JP2015505299A5 JP 2015505299 A5 JP2015505299 A5 JP 2015505299A5 JP 2014540570 A JP2014540570 A JP 2014540570A JP 2014540570 A JP2014540570 A JP 2014540570A JP 2015505299 A5 JP2015505299 A5 JP 2015505299A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- vlp
- polypeptide
- pharmaceutical composition
- found
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 26
- 102000004169 proteins and genes Human genes 0.000 claims 26
- 229920001184 polypeptide Polymers 0.000 claims 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 239000013598 vector Substances 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 102000040430 polynucleotide Human genes 0.000 claims 15
- 108091033319 polynucleotide Proteins 0.000 claims 15
- 239000002157 polynucleotide Substances 0.000 claims 15
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 14
- 241000714177 Murine leukemia virus Species 0.000 claims 11
- 101710177291 Gag polyprotein Proteins 0.000 claims 9
- 101710125418 Major capsid protein Proteins 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 7
- 239000002671 adjuvant Substances 0.000 claims 7
- 230000001086 cytosolic effect Effects 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 5
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 238000011144 upstream manufacturing Methods 0.000 claims 4
- 102000003886 Glycoproteins Human genes 0.000 claims 3
- 108090000288 Glycoproteins Proteins 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 230000008488 polyadenylation Effects 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558800P | 2011-11-11 | 2011-11-11 | |
| US61/558,800 | 2011-11-11 | ||
| US201261654157P | 2012-06-01 | 2012-06-01 | |
| US61/654,157 | 2012-06-01 | ||
| PCT/IB2012/002854 WO2013068847A2 (en) | 2011-11-11 | 2012-11-09 | Compositions and methods for treatment of cytomegalovirus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017151540A Division JP6657150B2 (ja) | 2011-11-11 | 2017-08-04 | サイトメガロウイルスの治療のための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505299A JP2015505299A (ja) | 2015-02-19 |
| JP2015505299A5 true JP2015505299A5 (OSRAM) | 2016-01-07 |
| JP6232544B2 JP6232544B2 (ja) | 2017-11-22 |
Family
ID=48290708
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540570A Active JP6232544B2 (ja) | 2011-11-11 | 2012-11-09 | サイトメガロウイルスの治療のための組成物及び方法 |
| JP2017151540A Active JP6657150B2 (ja) | 2011-11-11 | 2017-08-04 | サイトメガロウイルスの治療のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017151540A Active JP6657150B2 (ja) | 2011-11-11 | 2017-08-04 | サイトメガロウイルスの治療のための組成物及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9777043B2 (OSRAM) |
| EP (2) | EP2776567B1 (OSRAM) |
| JP (2) | JP6232544B2 (OSRAM) |
| KR (2) | KR102301463B1 (OSRAM) |
| CN (3) | CN107875382B (OSRAM) |
| AU (3) | AU2012335277B2 (OSRAM) |
| BR (2) | BR112014011229B1 (OSRAM) |
| CA (2) | CA3166278A1 (OSRAM) |
| DK (1) | DK2776567T3 (OSRAM) |
| ES (1) | ES2874233T3 (OSRAM) |
| MX (2) | MX387666B (OSRAM) |
| PT (1) | PT2776567T (OSRAM) |
| RU (2) | RU2019139064A (OSRAM) |
| WO (1) | WO2013068847A2 (OSRAM) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3330368B1 (en) | 2009-06-18 | 2021-07-21 | Kiyatec Inc. | Bioreactor system |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RS63430B1 (sr) | 2010-10-01 | 2022-08-31 | Modernatx Inc | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK3682905T3 (da) | 2011-10-03 | 2022-02-28 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf |
| US9777043B2 (en) | 2011-11-11 | 2017-10-03 | Variation Biotechnologies Inc. | Compositions and methods for treatment of cytomegalovirus |
| DE12858350T1 (de) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
| CA2867789C (en) | 2012-03-27 | 2022-06-14 | Variation Biotechnologies Inc. | Methods for detection of anti-cytomegalovirus neutralizing antibodies |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP2914284B1 (en) * | 2012-10-30 | 2016-09-21 | Pfizer Inc. | Recombinant particle based vaccines against human cytomegalovirus infection |
| HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| WO2015193143A1 (en) | 2014-06-18 | 2015-12-23 | Morphosys Ag | Fusion proteins and uses thereof |
| KR101678740B1 (ko) * | 2014-10-24 | 2016-11-23 | 단국대학교 천안캠퍼스 산학협력단 | 세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질 |
| US12060391B2 (en) | 2015-03-16 | 2024-08-13 | The Broad Institute, Inc. | Constructs for continuous monitoring of live cells |
| WO2017068077A1 (en) | 2015-10-20 | 2017-04-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and products for genetic engineering |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| WO2017162265A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2018165631A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Cancer vaccine |
| JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物 |
| EP3784276A4 (en) * | 2018-04-24 | 2022-03-16 | Merck Sharp & Dohme Corp. | SCALABLE CHROMATOGRAPHY PROCEDURE FOR PURIFICATION OF HUMAN CYTOMEGALOVIRUS |
| KR20210013571A (ko) | 2018-05-04 | 2021-02-04 | 스파이바이오테크 리미티드 | 백신 조성물 |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| BR112021024157A2 (pt) * | 2019-05-31 | 2022-04-26 | Variation Biotechnologies Inc | Composições imunoterapêuticas para tratamento de glioblastoma multiforme |
| JP2022536364A (ja) | 2019-06-13 | 2022-08-15 | ザ ジェネラル ホスピタル コーポレイション | 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法 |
| GB201910651D0 (en) * | 2019-07-25 | 2019-09-11 | Autolus Ltd | Virus-like particle |
| WO2021048081A1 (en) | 2019-09-09 | 2021-03-18 | Glaxosmithkline Biologicals Sa | Immunotherapeutic compositions |
| US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
| WO2022020800A2 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CN115948468A (zh) * | 2022-09-09 | 2023-04-11 | 青岛大学 | 一种人巨细胞病毒重组载体及其制备方法和应用 |
| WO2024243675A1 (en) * | 2023-06-02 | 2024-12-05 | Variation Biotechnologies Inc. | Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267965B1 (en) | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
| JPS61103895A (ja) * | 1984-10-26 | 1986-05-22 | Green Cross Corp:The | ＨＢｓＡｇの精製方法 |
| DE68929478T2 (de) * | 1988-01-29 | 2004-04-29 | Aventis Pasteur | Rekombinante CMV-Neutralisierungsproteine |
| US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
| DE19856463B4 (de) * | 1998-11-26 | 2006-02-02 | Heinrich-Pette-Institut | Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren |
| DE19910044A1 (de) | 1999-03-08 | 2000-09-14 | Bodo Plachter | Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff |
| JP2003512305A (ja) | 1999-09-30 | 2003-04-02 | ユニバーシティ オブ ワシントン | 免疫学的に重要な単純疱疹ウイルス抗原 |
| EP1201750A1 (en) * | 2000-10-26 | 2002-05-02 | Genopoietic | Synthetic viruses and uses thereof |
| US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| WO2004058166A2 (en) | 2002-12-23 | 2004-07-15 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| US7419674B2 (en) | 2003-07-11 | 2008-09-02 | Alpha Vax, Inc. | Alpha virus-based cytomegalovirus vaccines |
| RU2290204C1 (ru) * | 2005-07-27 | 2006-12-27 | Общество с ограниченной ответственностью "Аванген" | Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани |
| JP2009544322A (ja) | 2006-07-27 | 2009-12-17 | リゴサイト ファーマシューティカルズ インコーポレイテッド | キメラウイルス様粒子 |
| US20090123494A1 (en) | 2007-07-31 | 2009-05-14 | William Staplin | Momlv-based pseudovirion packaging cell line |
| US20110250675A1 (en) | 2008-03-26 | 2011-10-13 | Life Technologies Corporaiton | Virus-Like Particle Mediated Cellular Delivery |
| GB0907935D0 (en) * | 2009-05-08 | 2009-06-24 | Henderson Morley Plc | Vaccines |
| US9777043B2 (en) | 2011-11-11 | 2017-10-03 | Variation Biotechnologies Inc. | Compositions and methods for treatment of cytomegalovirus |
| CN106102769A (zh) * | 2013-12-11 | 2016-11-09 | 促进军事医学的亨利·M·杰克逊基金会公司 | 人疱疹病毒三聚糖蛋白B、包含三聚gB的蛋白复合体及其作为疫苗的用途 |
-
2012
- 2012-11-09 US US14/357,423 patent/US9777043B2/en active Active
- 2012-11-09 CA CA3166278A patent/CA3166278A1/en active Pending
- 2012-11-09 MX MX2017017128A patent/MX387666B/es unknown
- 2012-11-09 JP JP2014540570A patent/JP6232544B2/ja active Active
- 2012-11-09 ES ES12847559T patent/ES2874233T3/es active Active
- 2012-11-09 WO PCT/IB2012/002854 patent/WO2013068847A2/en not_active Ceased
- 2012-11-09 PT PT128475597T patent/PT2776567T/pt unknown
- 2012-11-09 CA CA2889659A patent/CA2889659C/en active Active
- 2012-11-09 RU RU2019139064A patent/RU2019139064A/ru unknown
- 2012-11-09 DK DK12847559.7T patent/DK2776567T3/da active
- 2012-11-09 BR BR112014011229-0A patent/BR112014011229B1/pt active IP Right Grant
- 2012-11-09 BR BR122019027913-6A patent/BR122019027913B1/pt active IP Right Grant
- 2012-11-09 EP EP12847559.7A patent/EP2776567B1/en active Active
- 2012-11-09 CN CN201711042348.7A patent/CN107875382B/zh active Active
- 2012-11-09 CN CN202010272504.4A patent/CN111995664B/zh active Active
- 2012-11-09 AU AU2012335277A patent/AU2012335277B2/en active Active
- 2012-11-09 RU RU2014123465A patent/RU2737530C1/ru active
- 2012-11-09 KR KR1020147015909A patent/KR102301463B1/ko active Active
- 2012-11-09 MX MX2014005653A patent/MX353189B/es active IP Right Grant
- 2012-11-09 EP EP21152309.7A patent/EP3854416A1/en active Pending
- 2012-11-09 KR KR1020197025818A patent/KR102340558B1/ko active Active
- 2012-11-09 CN CN201280066355.XA patent/CN104271745A/zh active Pending
-
2017
- 2017-08-04 JP JP2017151540A patent/JP6657150B2/ja active Active
- 2017-08-22 US US15/683,355 patent/US11248026B2/en active Active
-
2018
- 2018-05-18 AU AU2018203538A patent/AU2018203538A1/en not_active Abandoned
-
2020
- 2020-11-03 AU AU2020264275A patent/AU2020264275B2/en active Active
-
2022
- 2022-02-11 US US17/670,052 patent/US12421283B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505299A5 (OSRAM) | ||
| RU2019139064A (ru) | Композиции и способы для лечения цитомегаловируса | |
| WO2021189571A1 (zh) | 一种高效诱导机体体液免疫应答的疫苗载体、其制备方法及用途 | |
| JP2009544318A5 (OSRAM) | ||
| JP2017537622A5 (OSRAM) | ||
| JP2019514373A5 (OSRAM) | ||
| JP2017160222A5 (OSRAM) | ||
| WO2018176103A1 (en) | "chimeric molecules and uses thereof" | |
| RU2015155821A (ru) | Вакцины против малярии | |
| JP2014519830A5 (OSRAM) | ||
| RU2014117068A (ru) | Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса | |
| JP2015506705A5 (OSRAM) | ||
| CN115838439B (zh) | 嵌合转换受体基因修饰的nk细胞制备方法及应用 | |
| JP2019512251A5 (OSRAM) | ||
| TW202130363A (zh) | 變異型ｒｓｖ ｆ蛋白質及其利用 | |
| JP2018524019A5 (OSRAM) | ||
| CN105555958A (zh) | 水疱性口炎病毒的改性基质蛋白 | |
| WO2023051701A1 (zh) | 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗 | |
| JP2017538443A5 (OSRAM) | ||
| US20210386850A1 (en) | Fusion protein | |
| CN117003856B (zh) | 一种靶向乙肝表面抗原的t细胞受体工程化t细胞 | |
| CN105031630A (zh) | 同时分泌pd-1中和抗体和gm-csf因子的肿瘤细胞疫苗及其制备方法 | |
| CN117660500A (zh) | 核酸构建体、载体、转基因免疫细胞及其应用 | |
| JP2025519475A (ja) | Ｈｂｖ表面抗原特異的ｔ細胞受容体およびその使用 | |
| WO2023039243A2 (en) | Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use |